Resumen de Investigación

Analyzed using Evidence Intelligence™

Intas Semaglutide is Non-Inferior to Innovator Semaglutide

Desarrollado con el marco Evidence Intelligence™ de Dediabetes

Última actualización 12 de septiembre de 2026

Key finding

LSM change in HbA1c was -1.50 vs. -1.65 in test vs. reference group.

This study evaluated the non-inferiority of Intas semaglutide compared to innovator semaglutide in patients with type 2 diabetes.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Extended (5–20+ y)

Risk of bias

Some Concerns

Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

This study evaluated the non-inferiority of Intas semaglutide compared to innovator semaglutide in patients with type 2 diabetes.

Clinical relevance

These findings suggest that Intas semaglutide is a viable alternative to the innovator product, potentially offering more accessible treatment options for patients with type 2 diabetes without compromising efficacy or safety.

Keep in mind

The effectiveness of Intas semaglutide remains unclear due to non-significant p-values. The study's sample size and demographic diversity were not specified. Potential long-term effects and outcomes were not assessed.

Published in

Referencia de la Revista

Publication details and source links for this paper.

Ambrish C, Anurag RKLL, Archit P, et al. Non-inferiority of Intas Semaglutide Compared to Innovator Semaglutide in Type 2 Diabetes. Metabolism Open. 2026;31:100489. doi:10.1016/j.metop.2026.100489

View DOI View on PubMed View on PMC

Efectos Principales

LSM change in HbA1c was -1.50% for Intas vs. -1.65% for innovator (p=0.3266).

Fasting blood glucose decreased by -21.9 mg/dL (p=0.9107).

Post-prandial blood glucose decreased by -37.4 mg/dL (p=0.9215).

Body weight and BMI decreased in the test group.

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Semaglutide and BMI, Body weight, Fasting Blood Glucose (FBG), and 3 more.

This study contributes evidence to

Intervention

Semaglutide

Outcome

BMI

Evidence topic

Weight Loss

Primary intervention

Semaglutide

Primary outcomes

BMI
Body weight
Fasting Blood Glucose (FBG)

Evidence topics

Weight Loss Glycemic Control HbA1c Reduction Post-Meal and OGTT Glucose

Primary intervention

Semaglutide

Primary outcomes

BMI Body weight Fasting Blood Glucose (FBG)

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

Evidence pairs

Relationships

Evidence topics

contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 72

Why it is useful

Contributes to 6 evidence relationships
Includes primary outcome data
Linked to 5 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Agrega evidencia relacionada a tu Evidence Tracker

Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.

Evidencia principal

Relación de evidencia

GLP-1 Receptor Agonists and HbA1c

Evidencia relacionada

Relación de evidencia

GLP-1 Receptor Agonists and Body Weight

Guardar evidencia

Relación de evidencia

GLP-1 Receptor Agonists and Postprandial and OGTT Glucose

Guardar evidencia

Core evidence

Study findings

The primary outcomes reported in this study.

BMI

Semaglutide → BMI

Evidence Intelligence™

EvidenceScore™: 85; Strong
ImpactScore™: 70; Positive
ConsistencyScore™: 80; consistent

Basado en 5 estudios

Add to Evidence Tracker

Body weight

Semaglutide → Body weight

Evidence Intelligence™

EvidenceScore™: 86; Strong
ImpactScore™: 76; Positive
ConsistencyScore™: 92; consistent

Basado en 13 estudios

Add to Evidence Tracker

Fasting Blood Glucose (FBG)

Semaglutide → Fasting Blood Glucose (FBG)

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 50; Neutral
ConsistencyScore™: unclear; Not enough independent studies

Basado en 1 estudio

Add to Evidence Tracker

Glucose iAUC (OGTT)

Semaglutide → Glucose iAUC (OGTT)

Evidence Intelligence™

EvidenceScore™: Strong; Score 79 · Based on 3 studies
ImpactScore™: 50; Neutral
ConsistencyScore™: 100; consistent

Basado en 3 estudios

Add to Evidence Tracker

HbA1c

Semaglutide → HbA1c

Evidence Intelligence™

EvidenceScore™: 88; Strong
ImpactScore™: 87; Very Positive
ConsistencyScore™: 88; consistent

Basado en 16 estudios

Add to Evidence Tracker

Treatment-emergent adverse events

Semaglutide → Treatment-emergent adverse events

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 50; Neutral
ConsistencyScore™: unclear; Not enough independent studies

Basado en 1 estudio

Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

La Evidencia Sugiere

Intas semaglutide showed a decrease in HbA1c by -1.5% compared to innovator.
Fasting blood glucose levels decreased by -21.9 mg/dL.
No new safety signals were identified in treatment-emergent adverse events.

A quién se aplica

Adults with type 2 diabetes.
Patients seeking alternatives to innovator semaglutide.

Tener en Cuenta

Results may not be generalizable to all populations with type 2 diabetes.
Further studies are needed to confirm long-term efficacy and safety.
The study did not report on the demographic characteristics of participants.

Entre Líneas

The effectiveness of Intas semaglutide remains unclear due to non-significant p-values.
The study's sample size and demographic diversity were not specified.
Potential long-term effects and outcomes were not assessed.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Desarrollado con el marco Evidence Intelligence™ de Dediabetes

This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.

Relaciones de evidencia relacionadas

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Medications

Detailed evidence

GLP-1 Receptor Agonists → HbA1c

Medications

Evidence Intelligence™

EvidenceScore™: 88; Strong
ImpactScore™: 87; Very Positive
ConsistencyScore™: 88; consistent

Basado en 16 estudios

View evidence

Medications

Detailed evidence

GLP-1 Receptor Agonists → Body Weight

Medications

Evidence Intelligence™

EvidenceScore™: 86; Strong
ImpactScore™: 76; Positive
ConsistencyScore™: 92; consistent

Basado en 13 estudios

View evidence

Incluido en estas colecciones de evidencia

Curated evidence collections and hubs this study is part of.

GLP-1 Receptor Agonists Evidence Hub

All studies on GLP-1 Receptor Agonists

16 studies

intervention_hub

Contributes to GLP-1 Receptor Agonists evidence base.

HbA1c Evidence Hub

All studies measuring HbA1c

16 studies

outcome_hub

Measures HbA1c as a key outcome.

Body Weight Evidence Hub

All studies measuring Body Weight

13 studies

outcome_hub

Measures Body Weight as a key outcome.

Recent Diabetes Research

Latest published studies

recency_collection

Published within the last 2 years.

Explora más en Evidence Explorer

Jump to pre-filtered views in Evidence Explorer.

All studies on Semaglutide and HbA1c

Intervention: SemaglutideOutcome: HbA1c

16 results

All studies on Semaglutide and Body weight

Intervention: SemaglutideOutcome: Body weight

13 results

All studies on Semaglutide

Intervention: Semaglutide

16 results

All studies measuring HbA1c

Outcome: HbA1c

16 results

All studies measuring Body weight

Outcome: Body weight

13 results

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Do GLP-1 Receptor Agonists lower HbA1c?

Strong Evidence

GLP-1 Receptor Agonists appear to lower HbA1c.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 88.2 | strong positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 45 supporting studies with consistent results and a positive effect signal.

View Full Evidence

Do GLP-1 Receptor Agonists affect body weight?

Strong Evidence

GLP-1 Receptor Agonists may affect body weight.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 85.8 | moderate positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 43 supporting studies with consistent results and a positive effect signal.

View Full Evidence

Do GLP-1 Receptor Agonists improve postprandial and ogtt glucose?

Strong Evidence

GLP-1 Receptor Agonists may improve postprandial and ogtt glucose.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
Glucose iAUC (OGTT)
EvidenceScore™ Strong | EvidenceScore™ 79.0 | neutral | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 10 supporting studies with consistent results and a positive effect signal.

View Full Evidence

Do GLP-1 Receptor Agonists affect body mass index?

Strong Evidence

GLP-1 Receptor Agonists may affect body mass index.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
BMI
EvidenceScore™ Strong | EvidenceScore™ 85.0 | moderate positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 20 supporting studies with consistent results and a positive effect signal.

View Full Evidence

Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Weight Loss Evidence Hub Glycemic Control Evidence Hub HbA1c Reduction Evidence Hub Post-Meal and OGTT Glucose Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on Semaglutide and HbA1c All studies on Semaglutide and Body weight All studies on Semaglutide and BMI All studies on Semaglutide and Glucose iAUC (OGTT)

Related research

Read related research summaries.

Semaglutide may reduce cardiovascular events in non-diabetic patients.Oral semaglutide reduces cardiovascular events in type 2 diabetes Semaglutide improves insulin sensitivity in adolescents with obesity Higher semaglutide doses improve glucose control in type 2 diabetes Novel Semaglutide Injection Shows Non-Inferior Glycemic Control

Sin anuncios. Sin rastreo.

Centrada en la evidencia, no en la publicidad.

Segura y privada

Tus datos siempre están protegidos.

Siempre al día

Se agregan nuevos estudios todos los días.